BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 2405360)

  • 1. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW; Wozniak SP
    Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
    Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Kastelan A; Marusić M; Zupancić-Salek S
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
    [No Abstract]   [Full Text] [Related]  

  • 3. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Sundberg B; Bolme P; Brattström C; Gahrton G; Johansen L; Lönnqvist B
    Transplant Proc; 1988 Jun; 20(3):494-8. PubMed ID: 3381257
    [No Abstract]   [Full Text] [Related]  

  • 4. Methylprednisolone, cyclosporine and methotrexate for prophylaxis of acute graft-versus-host disease.
    Yau JC; LeMaistre CF; Zagars GK; Williams LA; Meneghetti CM; Luke DR; Dunphy FR; Spinolo JA; Jagannath S; Spitzer G
    Bone Marrow Transplant; 1990 Apr; 5(4):269-72. PubMed ID: 2337738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract]   [Full Text] [Related]  

  • 6. Cyclosporine and methylprednisolone for prophylaxis of acute graft-versus-host disease.
    Shepherd JD; Shore TB; Reece DE; Barnett MJ; Klingemann HG; Buskard NA; Phillips GL
    Bone Marrow Transplant; 1988 Nov; 3(6):553-8. PubMed ID: 3063323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cyclosporine as prophylaxis for graft versus host disease in adults undergoing allogeneic bone marrow transplantation].
    Matsushita T; Akatsuka Y; Towatari M; Takeyama K; Miyamura K; Sugihara T; Minami S; Kodera Y
    Rinsho Ketsueki; 1989 Apr; 30(4):429-36. PubMed ID: 2671437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate vs Cyclosporin A as a single agent for graft-versus-host disease prophylaxis in pediatric patients with hematological malignancies undergoing allogeneic bone marrow transplantation from HLA-identical siblings: a single-center analysis in Japan.
    Koga Y; Nagatoshi Y; Kawano Y; Okamura J
    Bone Marrow Transplant; 2003 Jul; 32(2):171-6. PubMed ID: 12838282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
    Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
    Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
    [No Abstract]   [Full Text] [Related]  

  • 14. Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease.
    Russell JA; Woodman RC; Poon MC; Jones AR; Ruether BA
    Bone Marrow Transplant; 1994 Sep; 14(3):397-401. PubMed ID: 7994261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia.
    Storb R; Deeg HJ; Whitehead J; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Doney K; Farewell V
    N Engl J Med; 1986 Mar; 314(12):729-35. PubMed ID: 3513012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
    Forman SJ; Blume KG; Krance RA; Miner PJ; Metter GE; Hill LR; O'Donnell MR; Nademanee AP; Snyder DS
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2605-7. PubMed ID: 3079090
    [No Abstract]   [Full Text] [Related]  

  • 17. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
    Ruutu T; Volin L; Elonen E
    Transplant Proc; 1988 Jun; 20(3):491-3. PubMed ID: 3289191
    [No Abstract]   [Full Text] [Related]  

  • 18. Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis.
    Byrne JL; Stainer C; Hyde H; Miflin G; Haynes AP; Bessell EM; Russell NH
    Bone Marrow Transplant; 1998 Sep; 22(6):541-5. PubMed ID: 9758340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporine administration practices on bone marrow transplant units: a national survey.
    Caudell KA; Adams J
    Oncol Nurs Forum; 1990; 17(4):563-8. PubMed ID: 2119035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.